Sessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Read MoreSessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Read MoreSessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Read MoreJoin more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
Read MoreJoin more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
Read MoreJoin more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
Read More
In extensive-stage small-cell lung cancer (ES-SCLC), IMpower133 improved progression-free survival...
Read More
Researchers conducted the MATCH study to assess the clinical benefits of adding low-dose...
Read More
According to IMpower133 and CASPIAN, anti-PD-L1 blockades combined with etoposide and platinum...
Read More
Researchers studied neoadjuvant immunotherapy to produce a pathologic response in patients with...
Read More
Merkel Cell Carcinoma (MCC) was rare, and aggressive skin cancer became more common as the...
Read More
Cancer’s biological behavior was exceedingly complex, driven by the nonlinear interplay of...
Read More
Cutaneous squamous cell carcinoma was the most frequent type of skin cancer globally. The presence...
Read More
In the United States, almost 1.5 million cutaneous squamous cell cancer (cSCC) are identified...
Read More
Researchers previously demonstrated improved efficacy of acalabrutinib (A) obinutuzumab (O) vs. O...
Read More
Acalabrutinib (Acala) was a next-generation, highly selective, covalent Bruton tyrosine kinase...
Read More
Over the last 2 decades, treatment for chronic lymphocytic leukemia (CLL) has evolved...
Read More
For a study, researchers sought to see if patients with chronic lymphocytic leukemia (CLL) who...
Read More
Ublituximab is a new monoclonal antibody that targets a specific epitope on the antigen CD20....
Read More
To analyze the link between cachexia and prognosis among patients with extensive-stage small-cell...
Read More
